Final Patient Visit Concludes Annovis Bio's Phase II/III Alzheimer's Trial

Annovis Bio, Inc., a pharmaceutical company specializing in the development of innovative treatments for neurodegenerative conditions, has reached a pivotal milestone in its clinical research. The company has recently completed the final patient visit for its phase II/III clinical trial evaluating the effectiveness of buntanetap, a potential therapeutic agent for Alzheimer's disease (AD). This achievement is a significant step forward in the quest to provide new treatment options for patients suffering from this debilitating condition, according to Maria Maccecchini, Ph.D., who leads the company as its Founder, President, and CEO.
The clinical trial was designed to be a rigorous, randomized, double-blind, and placebo-controlled study to assess the efficacy, safety, and tolerability of buntanetap in patients with mild to moderate AD. The trial involved a dose-ranging approach, with participants receiving either a 7.5mg, 15mg, or 30mg dose of buntanetap or a placebo, in addition to their standard care, for a duration of 12 weeks. Out of the 353 patients who enrolled in the study across 54 sites in the United States, 327 successfully completed the trial, indicating a low dropout rate and the study's successful progression.
Buntanetap is a novel compound that targets the underlying causes of neurodegeneration by inhibiting the formation of various neurotoxic proteins, including amyloid beta, tau, alpha synuclein, and TDP43. By doing so, it aims to enhance synaptic transmission, axonal transport, and reduce neuroinflammation, which are critical for preventing the degeneration and death of nerve cells. The drug's unique mechanism of action suggests it may have the potential to reverse the neurodegenerative process associated with AD.
Annovis Bio, Inc., based in Malvern, Pennsylvania, is at the forefront of clinical-stage drug development for neurodegenerative diseases such as AD and Parkinson's Disease (PD). The company is unique in its approach to developing a single drug that targets multiple neurotoxic proteins, with the goal of restoring axonal and synaptic activity. This innovative strategy is intended to address the memory loss and dementia associated with AD, as well as the body and brain dysfunction seen in PD.